Preventing Missing Data Among Concerns In US FDA’s Guidance On COVID-19 Symptom Assessment

 
• By Derrick Gingery
  
Closed up finger on keyboard with word CLINICAL TRIALS
The FDA wants investigators to remind outpatients to fill out COVID-19 PRO instruments to avoid missing data. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D